Beta-Secretase 1 (BACE1) Is Down-Regulated in Invasive Ductal Carcinoma of Breast by Yaghoobi, Hajar et al.
Reports of Biochemistry & Molecular Biology                                             
Vol.8, No.2, July 2019 
 
Original article 
 
 
1: University of Medical Sciences, Shahrekord, Iran. 
2: Department of Medical Biotechnology, School of Advanced Technologies, Shahrekord University of Medical Sciences, Shahrekord, Iran. 
3: Department of Medical Parasitology, School of Medicine, Zabol University of Medical Sciences, Zabol, Iran. 
4: Department of Medical Genetic, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 
5: Clinical Research Development Center (CRDU), Qom University of Medical Sciences, Qom, Iran. 
6: Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
7: Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
*Corresponding author: Mohammad Taheri; Tel: +98 21 23872572, Fax: +98 21 23872572, E-mail: mohammad_823@yahoo.com 
& Soudeh Ghafouri-Fard; Tel: +98 21 23872572; Fax: +98 21 23872572; E-mail: s.ghafourifard@sbmu.ac.ir. 
Received: 3 Apr, 2019; Accepted: 15 Aug, 2019 
www.RBMB.net 
 
Beta-Secretase 1 (BACE1) Is Down-Regulated in 
Invasive Ductal Carcinoma of Breast 
     
Hajar Yaghoobi1, 2, Hakim Azizi3, Mehdi Banitalebi-Dehkordi1,  
Fatemeh Mohammad Rezaei4, Shahram Arsang-Jnag5,  
Mohammad Taheri*6, Soudeh Ghafouri-Fard*7 
 
Abstract 
Background: The enzyme beta-secretase 1 (BACE1) and its antisense transcript (BACE1-AS) have been 
implicated in the pathogenesis of Alzheimer's disease. Moreover, several lines of evidence point to their 
contribution in tumorigenesis. 
Methods: In the present study, we evaluated expression of BACE1 mRNA (BACE1) and BACE1-AS in 54 
breast cancer tissues and 54 adjacent non-cancerous tissues (ANCTs) from the same patients using quantitative 
real-time PCR.  
Results: BACE1 was significantly down-regulated in tumoral tissues compared with ANCTs, while BACE1-
AS expression was not significantly different between tumoral tissues and ANCTs. The Bayesian Multilevel 
model showed a significant difference in BACE1 expression between stage 1 and 2 cancers after age-effect 
adjustments. BACE1-AS expression was significantly greater in ER-positive than in ER-negative samples 
(P=0.01). BACE1 and BACE1-AS expression were not correlated with patient ages in any sample sets.  
Conclusions: Significant correlations were detected between expression of these genes in both tumoral tissues 
and ANCTs. The current study provides evidence for differential BACE1 expression in breast tissues and 
suggests further assessment of the role of BACE1 in the pathogenesis of cancer. 
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Introduction 
The enzyme beta-secretase 1 (BACE1) is involved 
in the primary step of proteolytic cleavage of 
amyloid precursor protein (APP), which is 
completed by the subsequent function of gamma-
secretase. Accumulation of the resultant amyloid 
beta (Abeta) peptide in neuritic plaque of 
Alzheimer's brain has underscored the role of 
BACE1 in the pathogenesis of this disorder and 
has been proposed as a therapeutic target in 
Alzheimer's disease (AD) (1). A long non-coding 
RNA (lncRNA) transcribed from the BACE1 gene  
 
 
(BACE1) antisense (AS) strand regulates its 
expression via a feed-forward loop. The observed 
up-regulation of BACE1-AS in human AD brains 
compared with matched controls provided further 
evidence for the participation of BACE1 and 
BACE1-AS in the pathogenesis of AD (2). The 
significance of BACE1 in the pathogenesis of 
cancer has also been the focus of other researchers. 
The presence of APP in the endothelium during 
vessel synthesis implies its participation in 
angiogenesis. Moreover, BACE1 inhibitors have 
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been shown to decrease endothelial cell 
proliferation and inhibit neoangiogenesis both in 
vitro and in vivo (3). Consistent with these studies, 
two independent studies have reported elevated 
APP levels in breast cancer cells (4, 5). 
Considering the regulatory role of BACE1-AS in 
BACE1 expression and subsequent APP 
production (2) on one hand, and the detected high 
APP abundance in breast cancer cells (4) on the 
other, we hypothesized that BACE1 and BACE1-
AS expression in breast cancer tissues might differ 
from that in corresponding adjacent non-cancerous 
tissues (ANCTs). Further evidence for our 
hypothesis were provided by a growing number of 
studies reporting the role of lncRNAs in breast 
cancer (6-8) and the observed up-regulation of the 
lncRNA BACE1-AS by several cell stressors (9), 
which might be present in the cancer 
microenvironment as well. Consequently, we 
performed the present study to evaluate BACE1 
and BACE1-AS expression in invasive ductal 
carcinoma samples and their paired ANCTs. 
 
Materials and methods 
Patients 
In the present study, we recruited 54 patients with 
invasive ductal carcinoma of breast who were 
hospitalized in Sina and Farmanieh hospitals 
(Tehran, Iran) for surgical removal of breast mass. 
The diagnosis of cancer was confirmed through 
histopathological examination. Hormone receptor 
status and other relevant information were 
extracted from medical records. All patients 
signed written informed-consent forms. The 
study protocol was approved by the local ethical 
committee of Shahid Beheshti University of 
Medical Sciences. Tumoral tissues and ANCTs 
were excised and transferred in liquid nitrogen to 
the Medical Genetics Laboratory for further 
assessments. 
RNA extraction, cDNA synthesis, and expression 
analysis 
RNA was extracted and cDNA synthesized using 
TRIzol™ Reagent (Invitrogen, Carlsbad, CA, 
USA) and a RevertAid First Strand cDNA 
Synthesis Kit (TaKaRa, Japan), respectively, 
according to company protocols. Relative BACE1 
and BACE1-AS expression were compared 
between tumoral tissues and ANCTs using 
TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems) in a Rotor Gene 6000 Corbett Real-
Time PCR System. Expression was normalized to 
the hypoxanthine-guanine phosphoribosyl 
transferase gene (HPRT). The primer sequences 
are shown in Table 1.  
 
Table 1. Nucleotide sequences of primers and probes used in the study. 
Product 
length 
Primer and probe sequences Gene name 
88 
F: AGCCTAAGATGAGAGTTC 
HPRT1 R: CACAGAACTAGAACATTGATA 
FAM -CATCTGGAGTCCTATTGACATCGC- TAMRA 
79 
F: CCAAGACGACTGTTACAA 
BACE1 R: GAAGCCCTCCATGATAAC 
FAM-TTGCCATCTCACAGTCATCCAC-TAMRA 
113 
F: GACACTGTACCATCTCTTTTACCC 
BACE1-AS R: CACCACCAACCTTCGTTTGC 
FAM - AGTCCACTCACGGAGGAGGTCGCC -TAMRA 
 
Statistical methods 
Statistics were analyzed using R software version 
3.0.5 and SPSS 18 (Chicago, IL, USA). The 
Spearman correlation and Bayesian Multilevel 
model were used. Kruschke's Bayesian estimation 
was used to assess the significance of mean 
expression differences between tumoral tissues  
 
and ANCTs. A student-t prior distribution was 
assumed for parameters with 200,000 iteration 
and 5000 burn-outs. The 95% highest density 
interval (HDI) values were calculated based on 
Bayesian approach. The difference between 
relative mean gene expression values in patient 
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categories was evaluated using Tukey's 
honest significance test. CT values were 
corrected for the efficiencies of each primer 
set. The pairwise correlations between 
relative BACE1 and BACE1-AS transcripts 
levels in each set of samples were calculated 
using the regression model. 
 
Results 
Patient demographic and clinical features 
Patient demographic and clinical features are 
shown in Table 2.
 
Table 2. Patient demographic and clinical features. 
Variables Values 
Age (years) (mean± SD) 51.79 ± 13.54 (29-81) 
Menarche age (years) (mean± SD) 13 ± 1.65 (10-18) 
Menopause age (years) (mean± SD) 44.91 ± 14.91 (38-60) 
First pregnancy age (years) (mean± SD) 18.04 ± 8.36 (14-32) 
Breast feeding duration (months) (mean± SD) 41.62 ± 34.1 (3-120) 
Positive family history for other cancers (%) 17% 
Cancer stage (%) 
I 30.8 
II 28.8 
III 30.8 
IV 9.6 
Overall grade (%) 
I 17 
II 49 
III 34 
Mitotic rate (%) 
I 45.2 
II 42.9 
III 11.9 
Tumor size (%) 
<2 cm 32 
≥2 cm, <5 cm 66 
≥5 cm 2 
Estrogen receptor (%)  
Positive 87.8 
Negative 12.2 
Progesterone receptor (%)  
Positive 77.1 
Negative 22.9 
Her2/neu expression (%)  
Positive 25 
Negative 75 
Ki67 expression (%)  
Positive 100 
Negative 0 
 
BACE1 and BACE1-AS expression in tumoral 
tissues and ANCTs 
BACE1 expression was significantly less in 
tumoral tissues than in ANCTs; however,  
BACE1-AS expression was not significantly 
different in the two tissue types (Fig. 1).  
 
 
The Bayesian t test results comparing 
BACE1 and BACE1-AS relative expression in 
tumoral tissues and ANCTs are shown in 
Table 3. 
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Fig. 1. Relative BACE1 and BACE1-AS expression in tumoral tissues and ANCTs. 
Table 3. Bayesian t test to compare relative gene expression between two paired groups (a: Tumor-ANCTs, b: computed from frequentist 
method, c: 95% highest density interval (HDI) 
Gene 
Posterior mean Relative 
Expression 
differencea 
SD 
Effect 
Size 
P valueb 95% HDIc 
Tumoral tissues ANCTs 
BACE1 -0.44±0.68 1.02±0.67 -1.637 0.48 -0.487 0.001 [-2.58, -0.71] 
BACE1-AS 0.42±0.43 0.63±0.5 -0.3562 0.51 0.094 0.499 [-1.37, 0.62] 
 
Association between expression levels and 
patients' clinical data  
We assessed associations between 
expression levels and cancer stages using the 
Bayesian Multilevel model after age-effect 
adjustments and found higher BACE1 
expression in stage 1 compared with stage 2 
 
 
cancers in a way that expression in stage 2 
cancers were 1.81 unit higher than stage 2 
cancers (Table 4); however, BACE1-AS 
expression was not significantly different 
between the various stages (Table 5). 
 
Table 4. Bayesian Multilevel results of association between BACE1 expression and stage with age-effect adjustments 
(Stage 1= Reference group). 
BACE1 expression Estimate SE P value 95% Credible Interval 
Stage2 1.81 1.25 0.035 [0.65, 4.28] 
Stage 3 0.38 1.28 0.141 [-2.14, 2.96] 
Stage 4 -0.29 1.77 0.8 [-3.68, 3.24] 
Age -0.03 0.04 0.272 [-0.11, 0.04] 
 
Table 5. Bayesian Multilevel results of association between BACE1-AS expression and stage with age-effect 
adjustments (Stage 1= Reference group). 
BACE1-AS expression Estimate SE P value 95% Credible Interval 
Stage 2 0.46 1.47 0.347 [-2.43, 3.34] 
Stage 3 0.33 1.42 0.543 [-2.43, 3.17] 
Stage 4 -2.14 2.1 0.482 [-6.28, 2.04] 
Age -0.06 0.05 0.248 [-0.15, 0.03] 
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We also assessed correlations between expression 
levels in each sample set and patients' ages. BACE1 
and BACE1-AS expression were not correlated with 
patients' ages in any sample sets (Table 6). 
 
Table 6. Spearman correlation between gene expression in each sample set and patients' ages. 
  
BACE1 BACE1-AS 
Group 
Tumoral tissues -0.252 0.059 
ANCTs -0.164 0.107 
 
We also evaluated associations between 
relative gene expression and 
clinicopathological data (Table 7). BACE1-
AS expression was significantly greater in 
estrogen receptor (ER)-positive than in ER-
negative samples (P=0.01). No significant 
gene expression differences were found 
between patient subgroups. 
 
Table 7. Association between BACE1 and BACE1-AS transcript levels and tumor characteristics. Mean ± standard deviation values of 
Efficiency ^ CT reference gene-Efficiency ^ CT target gene are presented. 
 
BACE1 P value BACE1-AS P value 
Age 
<55 years old vs. ≥55 years old 
3.06 (1.42) vs. 
91.45 (288.38) 
0.35 
327.39 (1.54) vs. 489.87 
(2.15) 
0.78 
ER Status 
ER (+) vs. ER (-) 
2.39 (1.26) vs. 
484.36 (1.17) 
0.71 
55.67 (282.95) vs. 1.47 
(3.61) 
0.01 
PR Status 
PR (+) vs. PR (-) 
571 (2.98) vs. 
7.699 (2.45) 
0.08 
63.68 (304.84) vs. 809.02 
(2.66) 
0.09 
HER2 Status 
HER2 (+) vs. HER2 (-) 
6.81 (2.36) vs. 
666.5 (3.04) 
0.12 
1.73 (1.97) vs. 312.08 
(1.49) 
0.47 
Tumor Grade 
Grade 1 vs. 2 
336.89 (419.44) 
vs. 10.6 (37.95) 
0.9 
56.93 (45.06) vs. 1.4 
(1.84) 
0.95 
Grade 1 vs. 3 
336.89 (419.44) 
vs. 6.42 (2.05) 
0.47 
56.93 (45.06) vs. 1.27 
(3.14) 
0.28 
Grade 2 vs. 3 
10.6 (37.95) vs. 
6.42 (2.05) 
0.24 1.4 (1.84) vs. 1.27 (3.14) 0.09 
 
Correlation between BACE1 and BACE1-AS 
expression in tumors and ANCTs 
Significant correlation was found between 
 
RACE1 and BACE1-AS expression in both tumors 
and ANCTs (Figs. 2A and 2B). 
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A 
 
 
B 
Fig. 2. Correlation between BACE1 and BACE1-AS expression in tumors (A) and ANCTs (B).
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Discussion 
In the present study we evaluated BACE1 and 
BACE1-AS expression in invasive ductal 
carcinoma of breast and found significantly less 
BACE1 in tumors than in ANCTs. BACE1 
catalyzes the primary step of APP production (1), 
which has been shown to be elevated in some 
human malignancies and to enhance cell 
proliferation (10). In breast cancer cell lines, APP 
expression was up-regulated by 
dihydrotestosterone and its expression was 
associated with cell proliferation. In addition, APP 
protein abundance has been suggested as a 
prognostic factor in ER-positive breast cancer 
patients (4). In addition, increased APP levels have 
been shown to increase tumorigenicity and 
invasiveness of aggressive breast cancer cells (5). 
However, BACE1 activity and abundance have 
not yet been assessed in breast cancer samples. 
Several lines of evidences have highlighted the role 
of BACE1 in the pathogenesis of other cancer 
types. BACE1 inhibitors have been suggested as 
putative therapeutic agents in some human 
malignancies as they suppressed the growth and 
angiogenesis of human glioblastoma and lung 
adenocarcinoma tumors in a xenograft animal 
model (3). BACE1 is also involved in the 
photolytic cleavage of the insulin receptor (IR). 
The soluble IR fragment (IRsol) generated by this 
enzymatic action is increased in the plasma of 
hepatic cancer patients (11). Our study showed 
different BACE1 expression patterns in breast 
cancer tissues than were seen in other malignancy 
types. A possible explanation for this discrepancy 
is the presence of a tissue-specific function for 
BACE1. On the other hand, as previous studies 
have shown up-regulation of APP in breast cancer 
tissues, we hypothesize that the observed down-
regulation of BACE1 in our study might be 
compensated by activation of or over-expression of 
gamma-secretase to accomplish the final step of 
APP production. Simultaneous analysis of BACE, 
gamma-secretase, and APP levels in a larger cohort 
of breast cancer patients might help clarify the role 
of these proteins in the pathogenesis of breast 
cancer. The similar level of BACE1-AS in tumoral 
tissues and ANCTs, despite the down-regulation of 
BACE1 in tumoral tissues as revealed by our study, 
might imply a defect in regulation of BACE1-AS  
 
expression or in the feed-forward loop between 
these two transcripts in tumoral tissues. The latter 
possibility is also reflected in the observed stronger 
correlation between these two transcripts in 
ANCTs than in tumoral tissues, as demonstrated 
by R2 values. Future studies are needed to assess 
the interaction between these two transcripts in 
cancerous and normal tissues. 
The Bayesian Multilevel model results showed 
a significant difference in BACE1 expression 
between stages 1 and 2 cancers after age-effect 
adjustments. Such a finding might imply a putative 
stage-specific signature for this lncRNA or its 
involvement in certain stages of cancer 
development, which should be assessed in larger 
patient cohorts.  
Previous animal studies have shown age-
dependent differential expression of BACE splice 
variants in brain tissues (12). Further evidence for 
age-dependent regulation of BACE1 in brain tissue 
included the observed down-regulation of miR-
186 as a negative regulator of BACE1 in aged 
brains (13); however, we found no correlations 
between BACE1 or BACE1-AS transcript levels in 
breast tissues and patient age. Such inconsistencies 
might be due to the presence of tissue-specific 
regulatory mechanisms for BACE1 expression.  
Finally, we found greater BACE1-AS 
expression in ER-positive than in ER-negative 
samples. Previous studies have shown an 
association between BACE1 activity and brain 
estrogen reduction both in female AD patients and 
animal models (14). Moreover, estrogen treatment 
significantly decreased BACE1 protein levels in an 
ER-dependent manner (15). The observed 
association between BACE1-AS expression and 
ER status suggest an extra level of complexity in 
estrogen-regulated BACE production. 
In conclusion, we demonstrated down-regulation 
of BACE1 in invasive breast cancer samples in 
association with some patient clinicopathologies. 
Future studies are needed to elaborate the role of 
BACE1 in breast cancer pathogenesis. 
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